Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco.

Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco.

Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco.

Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco. Also disclosed is a method of making such a product.

Abstract: Pharmaceutical compositions and methods of use therefor for reducing the desire to engage in smoking are disclosed. More specifically, the pharmaceutical composition utilizes an active ingredient to reduce the side effects of smoking cessation and to limit the molecular feedback caused by nicotine-mediated activation of acetylcholine receptors.

Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco. Also disclosed is a method of making such a product.

Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco. Also disclosed is a method of making such a product.

Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco. Also disclosed is a method of making such a product.

Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco. Also disclosed is a method of making such a product.

Abstract: Pharmaceutical compositions and methods of use therefor for reducing the desire to engage in smoking are disclosed. More specifically, the pharmaceutical composition utilizes an active ingredient to reduce the side effects of smoking cessation and to limit the molecular feedback caused by nicotine-mediated activation of acetylcholine receptors.

Abstract: An orally-enjoyable tobacco product includes a portion of smokeless tobacco comprising an active ingredient and either: (1) a collection of tobacco particles at least partially enclosed by a coating comprising a water-soluble non-crosslinked component and a substantially water-insoluble cross-linked component, or (2) a pouch comprising smokeless tobacco enclosed in a water-permeable wrapper. The active ingredient is selected from the group consisting of a mercaptan, camphor, borneol, isoborneol, bornyl acetate, isobornyl acetate, mono-bornyl succinate, mono-isobornyl succinate, mono-bornyl formate, and mono-isobornyl formate. The active ingredient is present in an amount effective to reduce or eliminate the sensory irritation arising from the smokeless tobacco. Also disclosed is a method of making such a product.

Abstract: The present invention relates to chemical compounds, pharmaceutical compositions and methods for treating tumors and cancer and diseases which involve angiogenesis including retinopathy, age-related macular degeneration, angiogenic skin disorders and inflammation, including chronic inflammatory diseases, such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, arthritis, lupus and scleroderma, among others.